Procter & Gamble Health Limited reported a 45% year-on-year surge in net profit to ₹961.5 million in Q1FY27, driven primarily by a one-time exceptional gain of ₹318 million from the sale of its office premises. Revenue from operations rose 7.4% to ₹3,637.1 million, reflecting steady organic growth in its pharmaceutical segment despite the significant impact of the non-recurring asset sale on bottom-line figures. The divergence between top-line growth and headline profit underscores that the earnings boost is not repeatable, with core operational profitability remaining relatively flat.

The Board of Directors approved the unaudited financial results for the quarter ended June 30, 2026, during a meeting held on August 6, 2026. The results were reviewed by the Audit Committee and subjected to a limited review by the company’s statutory auditors, Haribhakti & Co. LLP, who issued an unmodified conclusion pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance Overview

The company’s operational performance remained robust, with revenue from operations increasing from ₹3,387.4 million in Q1FY26 to ₹3,637.1 million in Q1FY27. This growth was supported by higher sales volumes and effective pricing strategies within its single primary reportable segment, Pharmaceuticals. Management attributed the sales growth to strong brand fundamentals, superior retail execution, and positive consumer response to new innovations.

EBITDA expanded by 10.3% to ₹996.0 million, indicating improved operating leverage. However, net profit before exceptional items declined slightly by 2.8% to ₹643.5 million, highlighting that the headline profit growth is largely attributable to the asset sale rather than core operational improvements.

Impact of Exceptional Item

The most material development in the quarter was the sale of the company’s office premises located at Worli. The property was sold for ₹333.4 million against a carrying amount of ₹15.4 million, resulting in a gain of ₹318.0 million. This gain has been classified as an exceptional item under Indian Accounting Standards (Ind AS).

Excluding this one-time gain, the company’s core profitability remained relatively flat compared to the previous year. The tax expense for the quarter stood at ₹329.7 million, comprising current tax of ₹310.3 million and deferred tax charge of ₹19.4 million.

What the Numbers Show

The divergence between the 7.4% revenue growth and the 45% net profit surge underscores the non-operational nature of the bottom-line improvement. While top-line growth suggests healthy demand for Procter & Gamble Health’s pharmaceutical products, investors should note that the earnings per share (EPS) figure of ₹57.92 includes the exceptional gain. The basic EPS before exceptional items was ₹38.77, down slightly from ₹39.87 in Q1FY26. This indicates that while the company is growing revenue, core margin expansion has been modest, and the significant profit jump is not repeatable in subsequent quarters.

Auditor’s Review

Haribhakti & Co. LLP, the statutory auditors, conducted their review in accordance with Standard on Review Engagements (SRE) 2410. They confirmed that the financial statements were prepared in accordance with Ind AS 34 "Interim Financial Reporting" and other generally accepted accounting principles in India. No subsidiaries, associates, or joint ventures were reported as of June 30, 2026.

procter & gamble health has fixed Thursday, August 27, 2026 as the record date for its 59th Annual General Meeting (AGM) and the payment of final dividend. The company announced that the AGM is scheduled to be held on Thursday, September 3, 2026. Shareholders registered in the records of the company on the record date will be eligible to attend the meeting and receive the dividend, subject to approval by members.

The final dividend payment is contingent upon approval by the shareholders at the ensuing AGM. If approved, the company stated that the dividend will be disbursed to eligible members by September 27, 2026. The notification updates the schedule previously communicated to the stock exchanges.

Key Schedule

The intimation was addressed to the Corporate Relations Department of The BSE Limited and the Listing Department of The National Stock Exchange of India Limited. The filing was signed by Zeal Rupani, Company Secretary of Procter & Gamble Health Limited.